Navigation Links
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

porine, methotrexate or PUVA (psoralen plus ultraviolet A light).

In February 2006, REMICADE was approved in the EU for the treatment of moderately-to-severely active UC in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or azathioprine, or who are intolerant to or have medical contraindications for such therapies. This approval made REMICADE the first and only biologic therapy approved to treat moderate-to-severe UC in the EU. In May 2007, REMICADE was approved in the EU for the treatment of severe, active Crohn's disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolert to, or have contraindications for, such therapies.

REMICADE is the only anti-TNF biologic therapy available as an IV form. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. In RA (3 mg/kg), CD (5 mg/kg), PsA (5 mg/kg), UC (5 mg/kg), PCD (5 mg/kg), and PsO (5 mg/kg), REMICADE is a two-hour infusion administered every 8 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year. In AS (5 mg/kg), REMICADE is a two-hour infusion administered every 6 weeks, following a standard induction regimen that requires treatment at weeks 0, 2 and 6.

Centocor discovered REMICADE and has exclusive marketing rights to the product in the United States.

Schering-Plough markets REMICADE in all countries outside of the United States, except in Japan and parts of the Far East where Tanabe Seiyaku, Ltd. markets the product and in China where Xian-Janssen markets REMICADE.

Important Safety Information

There are reports of serious inf
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
2. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
Post Your Comments:
(Date:3/27/2015)... Across the global healthcare landscape, the Medical ... development, market education, and regulatory compliance. As emerging markets ... is expected to increase in prominence and follow the ... to research by benchmarking firm, Best Practices, LLC, all ... Medical Affairs. Among companies in India ...
(Date:3/27/2015)... 2015 Object recognition technology has a unique ... elderly. The VelaSense ® mobile platform ... independent, productive and fulfilling lives. VelaSense ® will ... to identify objects from a one million object database, ... object databases for personal use. Visus ...
(Date:3/27/2015)... 2015  Holographic Optical Technologies of Augusta, ... medical imaging, is entering the world of consumer electronics ... April 20 th , 2015, the campaign will introduce ... and 22-inch displays will allow consumers to view fully ... In addition to the two displays, the company will ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... 16 The Focused Ultrasound Surgery Foundation has announced that eight ... Symposium on MR-guided Focused Ultrasound, scheduled for October 17 through ... , , ... will spotlight leading edge preclinical, translational and clinical research related to ...
... SARASOTA, Fla. , July 16 Roper Industries, Inc. (NYSE: ... due 2034 (CUSIP No. 776696AA4) (the "Notes") will accrue contingent interest for ... 2011 at an annual rate of 0.25% of the average market ... 13, 2010 . Contingent cash interest, which the Company has determined to ...
Cached Medicine Technology:MR-Guided Focused Ultrasound Symposium Announces Sponsors 2MR-Guided Focused Ultrasound Symposium Announces Sponsors 3Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest and Conversion Rate Adjustment 2
(Date:3/29/2015)... Lake Orion, Clarkston, Metamora, MI. (PRWEB) March 29, 2015 ... with Beaumont Hospital , offers comprehensive endometriosis treatment. ... offer patients in that area a closer hospital option. ... Joseph Mercy Oakland and McLaren Oakland. , ... that normally lines the inside of the uterus (the ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
(Date:3/29/2015)... March 29, 2015 The Claudia ... Women’s Cancer announce today that Dr. Beth Y. ... the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic ... Society of Gynecologic Oncology 46th Annual Meeting on Women's ... the Cedars-Sinai Women’s Cancer Program at the Samuel Oschin ...
(Date:3/29/2015)... The federal court overseeing hundreds ... in the U.S. District Court, Northern District of ... Conference for April 21st at 1:30 p.m. Court ... progress of product liability claims filed on behalf ... and other cardiovascular complications due to their use ...
(Date:3/29/2015)... Youth Villages will participate in a partnership with ... feasibility of implementing a Pay for Success model to ... families. , Third Sector Capital Partners Inc. ran a ... technical assistance throughout 2015 toward a Pay for Success ... chosen by Third Sector. The organization’s work with the ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Endometriosis 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4
... University of Maryland and the Maryland Municipal League are teaming ... that may help them cope with tight budgets. Based ... program will guide communities through a series of steps that ... program - Sustainable Maryland Certified - is expected to be ...
... a mastectomy for women with advanced breast cancer saves lives, ... That is the conclusion of a new study published early ... American Cancer Society. The study,s results indicate that treatments that ... be available to many patients. , After clinical trials in ...
... not always lower your risk for heart disease and ... of investigators, including two scientists from the Institute for ... Medical School (HMS)., The Institute researchers, Douglas P. Kiel, ... with the Framingham Heart Study, identified a gene that ...
... (HealthDay News) -- Lifestyle changes such as losing weight, drinking ... substantial reduction in breast cancer cases across an entire population, ... these modifiable risk factors. Although such models are often ... on things that women can,t change, such as a family ...
... N.J., June 25, 2011 In a new post-hoc ... (AACE/ACE) diabetes algorithm presented at the American Diabetes Association ... type 2 diabetes treated with JANUMET (sitagliptin/metformin HCl) tablets ... metformin as initial therapy. JANUMET is ...
... lower her risk of breast cancer by losing weight, drinking ... in the Journal of the National Cancer Institute ... lifestyle changes on absolute breast cancer risk, suggesting risk reductions ... across an entire population. Breast cancer risk models are ...
Cached Medicine News:Health News:Helping Maryland municipalities go green to save: New UMD initiative 2Health News:Helping Maryland municipalities go green to save: New UMD initiative 3Health News:Many advanced breast cancer patients do not receive recommended treatment 2Health News:Genetic study shows that low body fat may not lower risk for heart disease and diabetes 2Health News:Lifestyle Changes Might Alter Breast Cancer Rates 2Health News:In a new post-hoc analysis, significantly more patients achieved blood sugar goals with JANUMET 2Health News:In a new post-hoc analysis, significantly more patients achieved blood sugar goals with JANUMET 3Health News:In a new post-hoc analysis, significantly more patients achieved blood sugar goals with JANUMET 4Health News:New breast cancer risk model quantifies the impact of risk reduction 2